Welcome to our dedicated page for Biodexa Pharmaceuticals Plc SEC filings (Ticker: BDRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Biodexa Pharmaceuticals plc filings document a foreign private issuer that reports current information on Form 6-K and incorporates certain disclosures into Form S-8 and Form F-3 registration statements. The records cover preliminary annual results; pipeline disclosures for eRapa, MTX240 and tolimidone; clinical trial authorizations and enrollment updates; and material agreements such as the MTX240 license and collaboration arrangement.
Capital-structure disclosures describe ADS units, pre-funded warrants, Series L warrants, public-offering documents, ADR ratio matters and the relationship between ADSs and ordinary shares. Governance and corporate filings also cover executive and board appointments, exhibit-based press releases, and other foreign-issuer current reports tied to Biodexa’s biopharmaceutical development programs.
Biodexa Pharmaceuticals PLC has filed a pre-effective amendment to register the resale of up to 127,754,750 Ordinary Shares, represented by 2,555,095 American Depositary Shares (ADSs), issuable upon exercise of pre-funded and Series M, N and O warrants held by a single selling shareholder. This is a resale registration; all sale proceeds from ADS resales will go to the selling shareholder, while Biodexa would receive cash only if the warrants are exercised for cash at their stated exercise prices.
The company reports 51,453,281 Ordinary Shares outstanding before warrant exercise and up to 179,208,031 Ordinary Shares assuming all warrants are fully exercised, indicating substantial potential dilution. Biodexa remains a clinical-stage biopharmaceutical company focused on eRapa for FAP and NMIBC, MTX240 for GIST, and tolimidone for type 1 diabetes, with fast track designation for eRapa and a $3.0 million CPRIT grant supporting its Phase 3 FAP program. Recent financing activity includes a July 2026 registered direct offering, a warrant inducement, and a private placement, each issuing warrants now covered by this resale registration.
Biodexa Pharmaceuticals PLC reported that shareholders approved all four resolutions at a General Meeting on July 29, 2026, including a one-for-10,000 reverse stock split of its ordinary shares, which have a nominal value of £0.000001 each. Shareholders also authorized the allotment of up to £25,000,000 for future share issuances through the 2029 annual general meeting and approved new Articles of Association reflecting these changes.
The share capital reorganization, effective from 08.00 BST (03.00 EDT) on July 30, 2026, reduces the number of ordinary shares outstanding by a factor of 10,000. Following the reorganization, 51,453,281 ordinary shares of £0.000001 each will be outstanding, equivalent to 1,029,063 American Depositary Shares (ADSs), the same number of ADSs as before. Concurrently, the ratio of ordinary shares per ADS will change from 500,000:1 to 50:1. The company states that these adjustments do not change the proportional ownership of holders of ordinary shares or ADSs, other than potential effects from the treatment of fractional entitlements.
Biodexa Pharmaceuticals PLC is registering for resale up to 1,277,547,500,000 Ordinary Shares represented by 2,555,095 American Depositary Shares, all issuable upon exercise of pre-funded, Series M, Series N and Series O warrants held by existing investors. All sale proceeds will go to the selling shareholders; Biodexa will receive cash only if these warrants are exercised, primarily at $2.85 per Depositary Share or $0.0001 for pre-funded warrants.
Total Ordinary Shares outstanding could rise from 452,032,808,922 to 1,729,580,308,922 if all warrants are exercised, creating substantial potential dilution and overhang. Biodexa is a clinical-stage biopharmaceutical company advancing eRapa (fast track designation, Phase 3 in FAP and Phase 2 in NMIBC), MTX240 for GIST and tolimidone for type 1 diabetes, while de-prioritizing MTX110 and closing its Cardiff laboratory. Recent July 1, 2026 financings, including a registered direct offering, a warrant inducement and a private placement, generated aggregate gross proceeds of approximately $0.8 million, $1.7 million and $1.0 million, respectively. Audit reports on recent financial statements contain explanatory paragraphs regarding Biodexa’s ability to continue as a going concern.
Biodexa Pharmaceuticals PLC has called a General Meeting for 29 July 2026 to approve a major share capital reorganisation and new share issuance authorities.
The company proposes a 10,000:1 consolidation of its existing ordinary shares, immediately followed by a subdivision into new ordinary shares of £0.000001 and a new class of E deferred shares. The board explains this is intended to rationalise an exceptionally large number of shares while keeping shareholder rights and proportional ownership unchanged, although holders of fewer than 10,000 shares would lose their ordinary shareholding after consolidation.
The company also seeks authority to allot shares or rights over shares up to an aggregate nominal value of £25,000,000.00, and to disapply statutory pre-emption rights on the same nominal amount until the annual general meeting to be held in 2029. Management notes this flexibility is aimed at acquisitions and financings to expand a pipeline focused on rare and orphan products and oncology. A related resolution would adopt new articles of association to reflect the new E deferred shares. The ratio of American Depositary Shares would change so that each ADS represents 50 new ordinary shares, with the total number of ADSs remaining the same.
Biodexa Pharmaceuticals PLC filed a Prospectus Supplement to its Form F-1 and a Form 6-K describing a set of securities transactions. The supplement covers the resale registration of 299,261,500,000 ordinary shares, represented by 598,523 ADSs, and the Company disclosed Offerings consisting of a Registered Direct Offering, concurrent private placements and a warrant inducement to raise proceeds.
The Registered Offering includes the sale of 82,809 ADSs at $2.85 each and 200,143 Registered Pre-Funded Warrants at $2.8499 each (each pre-funded warrant exercisable for one ADS at $0.0001). The Company also agreed to issue multiple series of unregistered warrants (Series M, N and O) contingent on shareholder approval. Aggregate gross proceeds from the Offerings and the Warrant Inducement are stated as approximately $3.54 million. The Prospectus Supplement incorporates a Form 6-K and a press release dated June 30, 2026.
Biodexa Pharmaceuticals PLC amends its March 30, 2026 prospectus to incorporate a prospectus supplement registering for resale up to 943,000,000 ordinary shares (represented by 1,886 ADSs). The supplement incorporates a Form 6-K describing a set of concurrent financings: a registered direct offering of 82,809 ADSs and 200,143 registered pre-funded warrants, concurrent private placements of 350,877 unregistered pre-funded warrants and private warrants, and related inducement warrants, subject in several cases to shareholder approval. The transactions are expected to generate aggregate gross proceeds of approximately $3.54 million before fees and are arranged with a placement agent paid an 8.0% cash fee. The supplement and Form 6-K describe exercise prices, beneficial ownership limits (4.99% or 9.99% at investor option), registration rights and customary closing conditions.
Biodexa Pharmaceuticals PLC amends its prospectus to register 109,500,000 ordinary shares (represented by 219 ADSs) for resale by selling shareholders. This Prospectus Supplement incorporates a Form 6-K describing concurrent financing arrangements including a registered direct offering of 82,809 ADSs and 200,143 registered pre-funded warrants at prices of $2.85 and $2.8499, respectively.
The Form 6-K also describes private placements of additional pre-funded warrants and warrants (Series M, N and O) exercisable upon shareholder approval, a warrant inducement arrangement, and an expected aggregate gross proceed estimate of approximately $3.54 million. Shareholder approval is required for the issuance and exercise of the Series M/N/O warrants.
Biodexa Pharmaceuticals PLC amends its March 30, 2026 prospectus to register the resale of 1,701,500,000 ordinary shares represented by 3,403 ADSs.
The supplement also discloses a registered direct offering of 82,809 ADSs at $2.85 per ADS and sale of 200,143 registered pre-funded warrants at $2.8499, concurrent private placements of 350,877 unregistered pre-funded warrants and unregistered warrants (Series M/N/O) exercisable subject to shareholder approval. Aggregate gross proceeds from the described transactions are expected to be approximately $3.54 million, and certain warrants have an exercise price of $0.0001 (pre-funded) or $2.85 (Series M/N/O). Several issuances and exercises are conditioned on shareholder approval and the resale registration process.
Biodexa Pharmaceuticals PLC files a prospectus supplement and Form 6-K describing completed and follow-on offerings and related warrant arrangements.
The supplement registers up to 97,800 ADSs (representing 48,900,000,000 Ordinary Shares), 1,219,512 ADSs (representing 609,756,000,000 Ordinary Shares) and 30,487 ADSs (representing 15,243,500,000 Ordinary Shares) underlying various warrants. The company completed a “best efforts” offering and separately agreed a Registered Direct Offering and private placements providing aggregate expected gross proceeds of approximately $3.54 million, subject to closing and shareholder approval.
Biodexa Pharmaceuticals PLC amends its March 30, 2026 prospectus to cover the resale of 171,500,000 Ordinary Shares represented by 343 American Depositary Shares. The supplement incorporates a Form 6-K disclosing a series of concurrent financings: a registered direct offering, private placements of pre‑funded warrants and contingent warrants, and a warrant inducement.
The company agreed to sell 82,809 ADSs at $2.85 and 200,143 Registered Pre‑Funded Warrants at $2.8499, with additional unregistered pre‑funded warrants and exercisable warrants contingent on shareholder approval. Aggregate gross proceeds are expected to be approximately $3.54 million, subject to closing conditions.